Twist Bioscience Corp (NASDAQ:TWST) insider William Banyai sold 25,000 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $53.15, for a total transaction of $1,328,750.00. Following the transaction, the insider now owns 539,635 shares in the company, valued at approximately $28,681,600.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
William Banyai also recently made the following trade(s):
- On Monday, June 15th, William Banyai sold 11,000 shares of Twist Bioscience stock. The stock was sold at an average price of $38.15, for a total transaction of $419,650.00.
- On Monday, June 1st, William Banyai sold 20,113 shares of Twist Bioscience stock. The stock was sold at an average price of $40.01, for a total transaction of $804,721.13.
- On Wednesday, May 20th, William Banyai sold 22,000 shares of Twist Bioscience stock. The stock was sold at an average price of $39.66, for a total transaction of $872,520.00.
Shares of TWST stock opened at $54.71 on Monday. The firm has a 50-day moving average of $40.68 and a 200-day moving average of $31.58. The company has a market cap of $2.24 billion, a P/E ratio of -12.38 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.26. Twist Bioscience Corp has a one year low of $18.52 and a one year high of $57.33.
Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.85) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.10). The company had revenue of $19.30 million for the quarter, compared to the consensus estimate of $17.18 million. Twist Bioscience had a negative net margin of 222.66% and a negative return on equity of 71.31%. Twist Bioscience’s quarterly revenue was up 41.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.93) EPS. As a group, research analysts expect that Twist Bioscience Corp will post -3 earnings per share for the current fiscal year.
Several research analysts have weighed in on TWST shares. Zacks Investment Research downgraded shares of Twist Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Cowen reiterated a “buy” rating on shares of Twist Bioscience in a report on Wednesday, July 8th. Finally, BidaskClub upgraded shares of Twist Bioscience from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Twist Bioscience presently has an average rating of “Buy” and a consensus target price of $42.00.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp grew its position in Twist Bioscience by 7.9% during the first quarter. State Street Corp now owns 959,140 shares of the company’s stock valued at $29,331,000 after buying an additional 70,093 shares during the period. Public Employees Retirement Association of Colorado bought a new position in Twist Bioscience during the first quarter valued at about $155,000. Fred Alger Management LLC bought a new position in Twist Bioscience during the first quarter valued at about $734,000. Perceptive Advisors LLC grew its position in Twist Bioscience by 49.3% during the first quarter. Perceptive Advisors LLC now owns 322,356 shares of the company’s stock valued at $10,380,000 after buying an additional 106,500 shares during the period. Finally, Redmile Group LLC bought a new position in Twist Bioscience during the first quarter valued at about $18,048,000. Institutional investors own 75.31% of the company’s stock.
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Recommended Story: Quiet Period Expirations
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.